Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas

Critical Care

Volumn 5, Issue 2, 2001, Pages 88-99

  Hoshino, Masami ^a   Haraguchi, Yoshikura ^b   Hirasawa, Hiroyuki ^c   Sakai, Motohiro ^a   Saegusa, Hiroshi ^a   Hayashi, Kazushiro ^a   Horita, Naoki ^a   Ohsawa, Hiroyuki ^a  

^a Tokyo Police Hospital   (Japan)

^b National Disaster Medical Center   (Japan)

^c CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Artificial pancrease; Coagulopathy; Diabetes mellitus; Multiple organ dysfunction syndrome; Tissue plasminogen activator plasminogen activator inhibitor 1 complex

Indexed keywords

ADRENALIN; ANTITHROMBIN III; CATECHOLAMINE; CORTICOTROPIN; DOPAMINE; GLUCAGON; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; LIOTHYRONINE; NORADRENALIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; THROMBOMODULIN; THYROTROPIN; THYROXINE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; ARTIFICIAL PANCREAS; BLOOD CLOTTING DISORDER; CALCULATION; CELL ACTIVATION; CELL DAMAGE; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; EVALUATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERCOAGULABILITY; HYPERINSULINEMIA; INTENSIVE CARE; JAPAN; MALE; MEASUREMENT; MEDICAL SOCIETY; MULTIPLE ORGAN FAILURE; PARAMETER; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEPSIS; STRESS; THROMBOCYTE COUNT;

EID: 0035065585     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc992     Document Type: Article

References (48)

1. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance
2. Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis
3. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular diseases
4. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
5. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus
6. Fibrinolysis and atherogenesis in the JCR: LA-cp rat in relation to insulin and triglyceride concentrations in blood
7. Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation?
8. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers
9. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction
10. Alterations in coagulation and fibrinolysis during sepsis
11. Factor VIIa a and antithrombin III activity during severe sepsis and septic shock in neutropenic patients
12. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared paterns of antithrombin III, protein C, and protein S deficiencies
13. Disseminated intravascular coagulation in a frequent complication of systemic inflammatory response syndrome
14. Soluble thrombomodulin increases in patients with disseminated intravascular coagulation and in those with multiple organ dysfunction syndrome after trauma: Role of neutrophil elastase
15. Hypercoagulable states
16. Blood levels of endothelin-1 and thrombomodulin in patients with disseminated intravascular coagulation and sepsis
17. The control of production and release of haemostatic factors in the endothelial cell
18. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity
19. Augumentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis
20. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose
21. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture
22. Synergistic augumentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids
23. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promotor by glucose in vascular smooth muscle cells
24. General discussion. Multiple organ failure IV: DIC bleeding from digestive tract
25. Glucose clamp technique: A method for quantifying insulin secretion and resistance
26. Normal splanchnic but impaired peripheral insulin-stimulated glucose uptake in cirrhosis
27. On the revised form of the comfirmatory tests in diagnostic criteria for DIC
28. Cardiovascular risk factors and the prediabetic syndrome
29. Hyper-insulinemia and hypofibrinolysis: Effects of short term optimized glycemic control with continuous insulin infusion in type II diabetic patients
30. Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances
31. Impaired fibrinolysis and insulin resistance in patients with hypertension
32. Relationships of blood pressure to fibrinolysis: Influence of anthropometry, metabolic profile and behavioural variables
33. Relationship between endothelial function and fibrinolysis in early hypertension
34. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease
35. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects
36. Insulin resistance syndrome and fibrinolytic activity: The northern Sweden MONICA study
37. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence
38. Blood coagulation and fibrinolysis in obese NIDDM patients
39. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus
40. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein matabolism and impaired fibrinolytic function
41. Tissue plasminogen activator (tPA) antigen in plasma: Correlation with different tPA/inhibitor complexes
42. Plasma tPA/PAI-1 complex and blood coagulability in patients with coronary artery disease
43. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states
44. Change in plasma levels of tissue plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation
45. Plasminogen activator inhibitors
46. Mechanisms of physiological fibrinolysis
47. Interleukin-2 induces activation of coagulation and fibrinolysis: Resemblance to the changes seen during experimental endotoxemia